María José López-Martínez
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
María José López-Martínez has a total of 11 co-authors. Here are the top co-authors by number of shared publications:
- Alberto Rábano
Neuropathology Department, Reina Sofía Alzheimer Center, CIEN Foundation , ISCIII, 28031 Madrid
1 shared publication - Alicia Uceda-Heras
Reina Sofía Alzheimer Center, CIEN Foundation, ISCIII, 28031 Madrid, Spain
1 shared publication - Francisco Javier López González
Reina Sofia Alzheimer Center, CIEN Foundation, ISCIII, Madrid Spain
1 shared publication - Héctor Rodrigo-Lara
Clinical & Experimental Neuroscience (NiCE), School of Medicine, Biomedical Research Institute of Murcia (IMIB Pascual Parrilla), Institute for Aging Research, Campus Mare Nostrum, UniWell, University of Murcia , 30120 Murcia
1 shared publication - Iago Rego-García
Reina Sofía Alzheimer Center, CIEN Foundation, ISCIII, 28031 Madrid, Spain
1 shared publication - Iván Burgueño-García
Reina Sofía Alzheimer Center, CIEN Foundation, ISCIII, 28031 Madrid, Spain
1 shared publication
Latest Publications
- Open Access
- 10 November 2024
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 13 (22) , 6755
Neuropathological Heterogeneity of Dementia Due to Combined Pathology in Aged Patients: Clinicopathological Findings in the Vallecas Alzheimer’s Reina Sofía Cohort
Background/Objectives: Clinicopathological research in late-life dementia has focused recently on combined neurodegenerative and vascular conditions underlying the high phenotypic heterogeneity of patients. The Vallecas Alzheimer’s Reina Sofía (VARS) cohort (n > 550), and particularly the series of associated brain donations (VARSpath cohort) are presented here. The aim of this study is to contribute to research in dementia with a well-characterized cohort from a single center. Methods: A total of 167 patients with complete neuropathological work-ups were analyzed here. The cohort is characterized by a high female predominance (79%), advanced age at death (88 yrs.), and a high frequency of ApoE-e4 haplotype (43%). Results: The main neuropathological diagnosis was Alzheimer’s disease (79.6%), followed by vascular dementia (10.2%) and Lewy body dementia (6%). Overall, intermediate-to-high cerebrovascular disease was observed in 38.9%, Lewy body pathology in 57.5%, LATE (TDP-43 pathology) in 70.7%, ARTAG in 53%, and argyrophilic grain disease in 12% of the patients. More than one pathology with a clinically relevant burden of disease was present in 71.1% of the brains, and a selection of premortem neuropsychological and functional scores showed significant correlation with the number of co-pathologies identified in postmortem brains. Conclusions: The VARS cohort, with thorough clinical follow-up, regular blood sampling, 3-Tesla MR, and a high rate of postmortem brain donation, can provide essential multidisciplinary data in the rising age of modifying therapies and biomarkers for Alzheimer’s disease and related dementias.
- 10 November 2024
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 13 (22) , 6755
Open AccessNeuropathological Heterogeneity of Dementia Due to Combined Pathology in Aged Patients: Clinicopathological Findings in the Vallecas Alzheimer’s Reina Sofía Cohort
Background/Objectives: Clinicopathological research in late-life dementia has focused recently on combined neurodegenerative and vascular conditions underlying the high phenotypic heterogeneity of patients. The Vallecas Alzheimer’s Reina Sofía (VARS) cohort (n > 550), and particularly the series of associated brain donations (VARSpath cohort) are presented here. The aim of this study is to contribute to research in dementia with a well-characterized cohort from a single center. Methods: A total of 167 patients with complete neuropathological work-ups were analyzed here. The cohort is characterized by a high female predominance (79%), advanced age at death (88 yrs.), and a high frequency of ApoE-e4 haplotype (43%). Results: The main neuropathological diagnosis was Alzheimer’s disease (79.6%), followed by vascular dementia (10.2%) and Lewy body dementia (6%). Overall, intermediate-to-high cerebrovascular disease was observed in 38.9%, Lewy body pathology in 57.5%, LATE (TDP-43 pathology) in 70.7%, ARTAG in 53%, and argyrophilic grain disease in 12% of the patients. More than one pathology with a clinically relevant burden of disease was present in 71.1% of the brains, and a selection of premortem neuropsychological and functional scores showed significant correlation with the number of co-pathologies identified in postmortem brains. Conclusions: The VARS cohort, with thorough clinical follow-up, regular blood sampling, 3-Tesla MR, and a high rate of postmortem brain donation, can provide essential multidisciplinary data in the rising age of modifying therapies and biomarkers for Alzheimer’s disease and related dementias.